United Therapeutics Announces Additional $420 Million Share Repurchase Program

United Therapeutics Announces Additional $420 Million Share Repurchase Program

PR Newswire

SILVER SPRING, Md., Feb. 4, 2013

SILVER SPRING, Md., Feb. 4, 2013 /PRNewswire/ --United Therapeutics
Corporation (NASDAQ: UTHR) today announced that its Board of Directors
authorized the repurchase of up to an additional $420 million of the company's
common stock. This program will become effective on March 4, 2013, and will
remain open for up to one year. Purchases may be made in the open market or
in privately negotiated transactions from time to time as determined by United
Therapeutics' management and in accordance with the requirements of the U.S.
Securities and Exchange Commission.

The company also announced that it had recently completed its
previously-announced $100 million repurchase program by purchasing
approximately 1,186,000 shares of common stock for a total of $57.1 million
during the fourth quarter of 2012.

"I am pleased that our board has authorized an additional $420 million in
share repurchases," remarked Martine Rothblatt, Ph.D., United Therapeutics'
Chairman and Chief Executive Officer. "We believe these are an appropriate
opportunity to return value to our shareholders."

About United Therapeutics

United Therapeutics is a biotechnology company focused on the development and
commercialization of unique products to address the unmet medical needs of
patients with chronic and life-threatening conditions. [uthr-g]

Forward-looking Statements

Statements included in this press release that are not historical in nature
are "forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include, among
others, statements regarding future repurchases of shares of our common
stock. These forward-looking statements are subject to certain risks and
uncertainties, such as those described in our periodic and other reports filed
with the Securities and Exchange Commission, that could cause actual results
to differ materially from anticipated results. These risks and uncertainties
include, among others, our ability to successfully execute repurchases on
favorable terms, and such forward-looking statements are qualified by the
cautionary statements, cautionary language and risk factors set forth in our
periodic reports and documents filed with the Securities and Exchange
Commission, including our most recent Annual Report on Form 10-K, Quarterly
Reports on Form 10-Q and Current Reports on Form 8‑K. We claim the protection
of the safe harbor contained in the Private Securities Litigation Reform Act
of 1995 for forward-looking statements. We are providing this information as
of February 4, 2013, and assume no obligation to update or revise the
information contained in this press release whether as a result of new
information, future events or any other reason.

SOURCE United Therapeutics Corporation

Website: http://www.unither.com
Contact: Andrew Fisher, +1-202-483-7000, Afisher@unither.com
Press spacebar to pause and continue. Press esc to stop.